Access Program Information
<p><strong>Metaiodobenzylguanidine (MIBG)</strong> is a substance that is taken up by <strong>neuroblastoma</strong> or <strong>pheochromocytoma</strong> tumor cells. MIBG is combined with radioactive iodine (131 I)in the laboratory to form a radioactive compound 131 I-MIBG. This radioactive compound delivers radiation specifically to the cancer cells and causes them to die. The purpose of this research protocol is to provides a mechanism to deliver <strong>MIBG therapy</strong> when clinically indicated, but also to provide a mechanism to continue to collect efficacy and toxicity data that will be provided</p>